Aquestive Therapeutics Received FDA Comments On Its Phase 3 Pharmacokinetic Study Protocol For Anaphylm (Epinephrine) Sublingual Film, indicating That The Company's Proposed Endpoints, Sample Size, And Statistical Analysis Are Reasonable
Portfolio Pulse from Benzinga Newsdesk
Aquestive Therapeutics has received comments from the FDA on its Phase 3 pharmacokinetic study protocol for Anaphylm (Epinephrine) Sublingual Film. The FDA indicated that the company's proposed endpoints, sample size, and statistical analysis are reasonable.
October 09, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aquestive Therapeutics' Phase 3 study protocol for Anaphylm has been deemed reasonable by the FDA. This positive feedback could potentially boost investor confidence in the company.
The FDA's positive feedback on Aquestive Therapeutics' Phase 3 study protocol for Anaphylm indicates that the company is on the right track with its research. This could potentially boost investor confidence in the company, leading to a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100